Shares of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) rose 6.4% on Monday . The company traded as high as $2.40 and last traded at $2.34. Approximately 712,683 shares changed hands during trading, an increase of 46% from the average daily volume of 488,502 shares. The stock had previously closed at $2.20.

EYPT has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. ValuEngine raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 29th. Finally, HC Wainwright set a $3.00 target price on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $4.85.

The company has a debt-to-equity ratio of 1.57, a quick ratio of 0.83 and a current ratio of 0.83. The firm has a market capitalization of $123.19 million, a price-to-earnings ratio of -4.10 and a beta of 0.97.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, September 12th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.08). The firm had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.67 million. Eyepoint Pharmaceuticals had a negative return on equity of 323.57% and a negative net margin of 1,795.71%. equities analysts predict that Eyepoint Pharmaceuticals Inc will post -0.34 earnings per share for the current year.

Several large investors have recently modified their holdings of EYPT. Renaissance Technologies LLC bought a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth $2,339,000. BlackRock Inc. bought a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth $304,000. Bard Associates Inc. bought a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth $189,000. Essex Investment Management Co. LLC bought a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth $170,000. Finally, Creative Planning bought a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth $162,000. 62.93% of the stock is currently owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

Featured Article: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.